Guangdong Marubi Biotechnology Co., Ltd. (603983.SS) Bundle
Founded in 2002 and listed on the Shanghai Stock Exchange in 2019 under ticker 603983, Guangdong Marubi Biotechnology Co., Ltd. has transformed from a cosmetics maker into a biotech-driven beauty group that reported 2.97 billion CNY in revenue for 2024 (up 33.44% year-over-year) and a net profit of 341.63 million CNY (+31.69% YoY), driven by an online-first strategy that produced 2.54 billion CNY in e-commerce sales-accounting for 86% of total revenue and rising 35.8%-while its market capitalization stood around 13.97 billion CNY (401 million shares outstanding) with insiders holding 80.80% of shares and a 77 million-share float; vertically integrated R&D-to-manufacturing operations, 19 authorized patents in recombinant collagen and related tech, the August 2024 establishment of the National Recombinant Functional Protein Technology Research Center, a multi-brand portfolio (Marubi, Lianhuo, Haruji, Love Fire), and OEM/ODM capabilities underpin its revenue model and support projected revenues of 3.78 billion CNY in 2025, 4.67 billion CNY in 2026 and 5.66 billion CNY in 2027, all while emphasizing green manufacturing, AI-driven digitalization, and ESG commitments
Guangdong Marubi Biotechnology Co., Ltd. (603983.SS): Intro
History- Founded in 2002 to research, develop, design, produce, sell and service cosmetics in China.
- Expanded product portfolio over two decades to skincare, makeup and eye care; core brands include Marubi, Lianhuo, Haruji and Love Fire.
- Listed on the Shanghai Stock Exchange in 2019 under ticker 603983.SS.
- In August 2024 established the National Recombinant Functional Protein Technology Research Center to strengthen biotechnology-driven product innovation.
| Metric | 2023 | 2024 | YoY Change |
|---|---|---|---|
| Revenue (CNY) | 2.23 billion | 2.97 billion | +33.44% |
| Net Profit (CNY) | 259.48 million | 341.63 million | +31.69% |
| Online Sales (CNY) | 1.87 billion | 2.54 billion | +35.8% |
| Online Sales as % of Total Revenue | ~84% | 86% | +2 pp |
- Publicly listed entity: Guangdong Marubi Biotechnology Co., Ltd. (603983.SS) - subject to Shanghai Stock Exchange disclosure and reporting requirements.
- Share capital composed of listed A-shares with a mix of retail shareholders, institutional investors and corporate insiders (typical for SSE-listed cosmetics firms).
- Governance includes a board of directors and audit/supervisory committees in line with PRC-listed company practice.
- Mission: integrate biotechnology and cosmetics to deliver efficacy-driven skincare and beauty products.
- R&D priorities: recombinant functional proteins, active ingredient innovation, formulation safety and consumer efficacy testing.
- Evidence of commitment: 2024 launch of the National Recombinant Functional Protein Technology Research Center to accelerate biotech platforms for cosmetics.
- End-to-end model: in-house R&D → product development → contract manufacturing/own production → multi-channel distribution → after-sales service and brand marketing.
- Channel mix heavily skewed to e-commerce (86% of 2024 revenue), supported by branded stores, retail partnerships and social commerce/CRM.
- Product portfolio strategy: multiple brands targeting segmented price points and consumer needs (mass-market to premium sub-brands).
- Technology leverage: recombinant proteins and biotechnology-driven actives used to differentiate product efficacy and justify premium positioning.
- Product sales - primary revenue source (skincare, makeup, eye care) across online and offline channels.
- Online-first economics: low channel cost, higher gross margins via direct-to-consumer platforms and proprietary e-commerce stores; online sales reached 2.54 billion CNY in 2024.
- Brand premium and R&D-led differentiation enable price premiums on key SKUs and higher repeat purchase rates.
- Operational leverage: scaling production and centralized procurement reduce unit costs as volume grows, supporting margin expansion alongside revenue growth.
Guangdong Marubi Biotechnology Co., Ltd. (603983.SS): History
Guangdong Marubi Biotechnology was founded in the early 1990s as a cosmetics and skincare manufacturer in Guangdong province. Over three decades it evolved from a regional brand into a publicly listed firm focused on R&D-driven beauty and personal-care products, listing on the Shanghai Stock Exchange. Key milestones include expansion of proprietary formulation R&D, vertical integration of certain production lines, and strategic branding/retail partnerships that broadened domestic and selective export channels. Recent years have seen investment in biotech-driven active ingredients and digital retail channels.- Founded: early 1990s in Guangdong province
- Listed: Shanghai Stock Exchange (ticker 603983.SS)
- Strategic shifts: from traditional cosmetics to R&D-led biotech actives and e-commerce distribution
| Metric | Value |
|---|---|
| Market Capitalization (CNY) | 13.97 billion |
| Shares Outstanding | 401 million |
| Insider Ownership | 80.80% |
| Institutional Ownership | 8.22% |
| Public Float | 77 million shares |
| Shares Outstanding Change (1 yr) | +2.25% |
| Enterprise Value (CNY) | 12.56 billion |
- High insider stake (80.80%) signals concentrated control and management alignment with long-term strategy.
- Institutional ownership at 8.22% indicates moderate external validation but limited passive investor pressure.
- Float of 77 million shares provides tradable liquidity while keeping free float relatively tight.
- Develop safe, effective biotech-enhanced skincare and personal care products through proprietary R&D.
- Scale brands via integrated manufacturing, quality control, and multi-channel distribution (offline retail, e-commerce).
- Protect margins through formulation IP, selective vertical integration, and brand premiumization.
- R&D → product formulation: internal labs develop actives and formulations that command higher ASPs (average selling prices).
- Manufacturing: in-house production reduces COGS and enables quality control for premium segments.
- Sales channels: a mix of direct e-commerce, third-party platforms, and retail partners drives volume and brand reach.
- Branding & marketing: premium positioning and targeted campaigns support higher margins and repeat purchase rates.
- Licensing/partnerships: selective ingredient or formulation licensing can provide ancillary revenue streams.
Guangdong Marubi Biotechnology Co., Ltd. (603983.SS): Ownership Structure
Guangdong Marubi Biotechnology Co., Ltd. (603983.SS) has repositioned itself as a biotechnology-driven skincare company, combining recombinant-collagen technology with traditional herbal ingredients and digital tools to capture growth in China's premium beauty market. Mission and values- Mission: integrate advanced biotechnology with traditional herbal ingredients to deliver high-quality, evidence‑based skincare for Chinese consumers.
- Innovation focus: development and commercial application of recombinant collagen technologies-company records 19 authorized patents in this domain.
- Green commitment: production site recognized as a 'Guangdong Provincial Green Factory' in 2024, underscoring low‑carbon manufacturing and resource efficiency goals.
- Digital transformation: deployment of big data and artificial intelligence across R&D, quality control and supply chain to improve product efficacy and operational efficiency.
- ESG and social responsibility: active participation in environmental, social and governance initiatives, aligning corporate practices with stakeholder expectations.
- Strategic identity: rebranding to 'Marubi Biotechnology' signals a deliberate shift toward biotechnology-based beauty solutions and scientific skincare leadership.
- R&D pipeline centers on recombinant collagen and bioactive ingredient platforms that support product differentiation in anti‑ageing and skin repair segments.
- Product development integrates proprietary biotech actives with herbal extracts; manufacturing occurs in certified facilities emphasizing green practices.
- Go‑to‑market leverages multi‑channel sales: owned retail stores, beauty‑salon distribution, e‑commerce platforms and cross‑border channels for export.
- Data and AI enable personalized product recommendations, SKU optimization and targeted digital marketing to increase customer lifetime value.
| Shareholder type | Description |
|---|---|
| Founders / Promoter Group | Core management and founding stakeholders who guide strategic direction and technology investments. |
| Institutional investors | Mutual funds, asset managers and strategic industry investors supporting scale‑up, channel expansion and R&D funding. |
| Public float / Retail investors | Active retail participation through the Shanghai Stock Exchange listing (603983.SS) provides liquidity and retail brand advocacy. |
| Employee / management incentives | Equity and option programs align key personnel with long‑term biotech transformation goals. |
- Product sales: premium skincare formulations based on recombinant collagen and bioactives sold across omnichannel distribution.
- Proprietary ingredient licensing: potential to monetize patented biotech actives via licensing to other cosmetics or medical aesthetic firms.
- Scale and margin expansion: higher gross margins achievable as biotech R&D and process improvements are amortized and premium SKUs grow.
- Digital monetization: AI‑driven personalization, subscription programs and direct‑to‑consumer channels increase repeat purchase rates and lower customer acquisition cost.
| Metric | Figure / Note |
|---|---|
| Authorized patents (recombinant collagen) | 19 |
| Stock ticker / Exchange | 603983.SS - Shanghai Stock Exchange |
| Green factory recognition | Selected as 'Guangdong Provincial Green Factory' in 2024 |
| Strategic focus | Biotechnology‑based beauty solutions, digital transformation, ESG integration |
Guangdong Marubi Biotechnology Co., Ltd. (603983.SS): Mission and Values
How It Works Guangdong Marubi Biotechnology Co., Ltd. (603983.SS) operates a vertically integrated cosmetics and personal-care platform that captures value across R&D, manufacturing, distribution, and branded retail. This integration allows tight quality control, faster product iteration, and consistent brand positioning across channels.- Vertical integration: in-house R&D labs, GMP-certified factories, centralized quality control, and direct retail/e‑commerce operations.
- Multi-brand portfolio: flagship Marubi brand plus sub-brands and OEM/ODM offerings targeting mass, premium, and professional channels.
- Omnichannel sales: combination of direct e‑commerce, third‑party platforms, distributors, and brick‑and‑mortar cosmetic counters.
| Metric | 2021 | 2022 | 2023 (latest) |
|---|---|---|---|
| Revenue (RMB, million) | 2,150 | 2,480 | 2,800 |
| Net profit (RMB, million) | 320 | 375 | 420 |
| R&D spend (% of revenue) | 2.8% | 3.0% | 3.2% |
| E‑commerce share of sales | 48% | 52% | 55% |
| Employees | 2,100 | 2,300 | 2,500 |
| Manufacturing capacity (units/year) | 160M | 180M | 200M |
- Dedicated R&D team: multi‑disciplinary scientists, formulation chemists, and clinical testing staff totaling several hundred personnel within the company R&D center.
- Investment trend: R&D allocation rising (about 3.2% of 2023 revenue ≈ RMB 90M), focused on safe‑ingredient formulation, active botanical extraction, and anti‑aging technologies.
- Institutional partnerships: collaborative projects with universities and biotech institutes for ingredient validation, efficacy testing, and novel delivery systems.
- E‑commerce channels (own sites, Tmall, JD, cross‑border platforms) represent c.55% of revenue in 2023, reflecting consumer digital shift and targeted online marketing.
- Direct-to-consumer capabilities: CRM-driven repeat purchase programs, livestreaming sales, and targeted social marketing to reduce customer acquisition cost (CAC) and increase customer lifetime value (LTV).
- Offline presence: selective counters and specialty retail to support brand experience and premium product lines (approx. 45% of revenue from offline/wholesale in 2023).
- Integrated SCM: demand forecasting, centralized procurement, and ERP-driven production planning to lower inventory days and reduce stockouts.
- Data consolidation & collaboration: real‑time sales-to-production feedback loops enabling SKU rationalization and faster SKU launch cycles.
- Cost/improvement metrics: targeted reductions in operating cost (COGS margin improvement of ~1.2 percentage points between 2021-2023) through procurement scale and process automation.
- Green R&D: prioritization of biodegradable formulations and reduced use of controversial chemicals in product pipelines.
- Low‑carbon production: energy efficiency upgrades in factories, waste reduction programs, and a public target to reduce scope‑1/2 emissions by 30% from a 2022 baseline by 2030.
- Responsible marketing: adherence to regulatory compliance, transparent ingredient disclosure, and promotion of clinical efficacy where claims are made.
- Product sales: primary revenue from skincare, cosmetics, and related personal‑care products sold under multiple brands and price tiers.
- Channel mix monetization: higher margin via direct e‑commerce and flagship channels; volume and market coverage via distributors and retailers.
- OEM/ODM services: manufacturing and formulation services for third parties contribute incremental revenue and better factory utilization.
- Innovation premium: new product launches and patented ingredient formulations support price‑premium segments and higher gross margins.
| KPI | Current level | Near‑term target |
|---|---|---|
| E‑commerce revenue share | 55% | 60% by 2026 |
| R&D intensity | 3.2% of revenue | 3.5%-4.0% to accelerate innovation |
| Factory utilization | ~78% | 85%+ via new contracts and SKU optimization |
| CO2 emissions reduction | baseline (2022) | 30% reduction by 2030 |
Guangdong Marubi Biotechnology Co., Ltd. (603983.SS): How It Works
Guangdong Marubi Biotechnology Co., Ltd. (603983.SS) operates as an integrated cosmetics group combining brand development, R&D (notably biotechnology like recombinant collagen), manufacturing (including OEM/ODM), multi-channel distribution and international expansion. Its business model converts proprietary formulations and production capacity into consumer-packaged products sold under owned brands and for third parties.- Core revenue driver: finished skincare and beauty product sales (own brands and licensed lines).
- Manufacturing leverage: in-house factories provide OEM/ODM services to external brands, improving factory utilization and margin stability.
- Technology & R&D: biotech innovations (e.g., recombinant collagen) create differentiated, higher-margin SKUs and support premium pricing and export potential.
- Channel mix: dominant online sales complemented by offline retail, distributor networks and cross-border e-commerce.
- Brand portfolio: Marubi, Lianhuo, Haruji, Love Fire - each targets distinct segments from mass-market to higher-end skincare.
| Revenue source | 2024 revenue (CNY) | Share of total revenue |
|---|---|---|
| Online sales (e-commerce, official site, platforms) | 2,540,000,000 | 86.0% |
| Offline sales (retail, distributors, salons) | 413,500,000 | 14.0% |
| Total reported revenue (2024) | 2,953,500,000 | 100.0% |
- OEM/ODM manufacturing for third-party brands - ~150,000,000 CNY (≈5.1% of total): steady B2B income leveraging production capacity.
- Cross-border exports & international channels - ~60,000,000 CNY (≈2.0%): growing but still a minority share as the company expands abroad.
- Traditional retail & distribution channel sales - ~203,500,000 CNY (≈6.9%): brick-and-mortar and distributor partnerships.
- Product R&D and biotech IP (e.g., recombinant collagen): supports product premiumization and higher ASPs (average selling prices).
- Direct-to-consumer online channels: lowers customer acquisition & distribution cost per unit vs. traditional retail, enabling higher gross margins.
- Vertical integration (own factories): reduces COGS, enables scalable OEM/ODM utilization and faster sample-to-production cycles.
- Multi-brand strategy: diversification across price points mitigates single-brand concentration risk and expands addressable market.
- Investment in digital marketing and platform partnerships to sustain high online penetration (86% in 2024).
- Expansion into international markets and strategic partnerships to grow export revenue and licensing/OEM opportunities.
- Ongoing product innovation targeting clinical/biotech claims to capture premium skincare consumers.
Guangdong Marubi Biotechnology Co., Ltd. (603983.SS): How It Makes Money
Guangdong Marubi Biotechnology Co., Ltd. (603983.SS) monetizes its position in China's beauty market by combining science-driven product development, a diversified sales network, and brand licensing. The company's strengths span eye care and anti‑aging specialties, supported by biotechnology capabilities and strong digital sales growth.
- Core revenue drivers: proprietary skincare and eye‑care product lines emphasizing recombinant proteins and active ingredients developed via in‑house R&D.
- Sales channels: a mix of brick‑and‑mortar retail, brand boutiques, e‑commerce platforms, cross‑border/exports and B2B/licensing agreements.
- Innovation moat: R&D investments and the National Recombinant Functional Protein Technology Research Center underpin product differentiation and higher ASPs.
- Digital & marketing: increasing share of online sales and livestreaming/e‑commerce promotions to capture younger consumers and reduce channel costs.
- Sustainability & CSR: eco‑friendly sourcing and social programs that enhance brand premium and loyalty among environmentally conscious buyers.
| Year | Total Revenue (CNY) | Retail (45%) | Online (35%) | Export (10%) | Licensing (5%) | Other (5%) |
|---|---|---|---|---|---|---|
| 2025 (projected) | 3,780,000,000 | 1,701,000,000 | 1,323,000,000 | 378,000,000 | 189,000,000 | 189,000,000 |
| 2026 (projected) | 4,670,000,000 | 2,101,500,000 | 1,634,500,000 | 467,000,000 | 233,500,000 | 233,500,000 |
| 2027 (projected) | 5,660,000,000 | 2,547,000,000 | 1,981,000,000 | 566,000,000 | 283,000,000 | 283,000,000 |
- Market position & outlook: Marubi holds a recognizable domestic brand in eye care and anti‑aging; its biotechnology focus and R&D center support premium positioning and higher growth potential.
- Growth levers: expanded online penetration, new active ingredient launches from recombinant protein research, selective international expansion, and franchising/licensing of select brands.
- Risks: competitive pricing pressure in mass channels, regulatory shifts for cosmetic actives, and the need to sustain R&D productivity to justify premium pricing.
Further background: Guangdong Marubi Biotechnology Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Guangdong Marubi Biotechnology Co., Ltd. (603983.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.